UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Thalidomide

The Lancet (British edition), 2004-05, Vol.363 (9423), p.1802-1811

2004

Volltextzugriff (PDF)

Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

Journal of clinical oncology, 2004-07, Vol.22 (13), p.2532-2539

2004

Volltextzugriff (PDF)

Thalidomide Metabolism by the CYP2C Subfamily

Clinical cancer research, 2002-06, Vol.8 (6), p.1964-1973

2002

Volltextzugriff (PDF)

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform

The pharmacogenomics journal, 2010-06, Vol.10 (3), p.191-199

2010

Volltextzugriff (PDF)

A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-independent Prostate Cancer

Clinical cancer research, 2001-07, Vol.7 (7), p.1888-1893

2001

Volltextzugriff (PDF)

Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

Journal of clinical oncology, 2000-02, Vol.18 (4), p.708-715

2000

Volltextzugriff (PDF)

Review of UCN-01 Development: A Lesson in the Importance of Clinical Pharmacology

Journal of clinical pharmacology, 2005-04, Vol.45 (4), p.394-403

2005

Volltextzugriff (PDF)

Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent

Biochemical pharmacology, 1998-06, Vol.55 (11), p.1827-1834

1998

Volltextzugriff (PDF)

Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues

Cancer research (Chicago, Ill.), 2003-06, Vol.63 (12), p.3189-3194

2003

Volltextzugriff (PDF)

Synthesis of Racemic cis-5-Hydroxy-3-phthalimidoglutarimide. A Metabolite of Thalidomide Isolated from Human Plasma

Journal of organic chemistry, 2005-11, Vol.70 (24), p.10117-10120

2005

Volltextzugriff (PDF)

Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice

Clinical cancer research, 2004-06, Vol.10 (12), p.4192-4197

2004

Volltextzugriff (PDF)

Thalidomide neuropathy in patients treated for metastatic prostate cancer

Muscle & nerve, 2001-08, Vol.24 (8), p.1050-1057

2001

Volltextzugriff (PDF)

Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study

Journal of clinical oncology, 2016-12, Vol.34 (34), p.4125-4131

2016

Volltextzugriff (PDF)

Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors

Journal of medicinal chemistry, 2004-04, Vol.47 (9), p.2219-2227

2004

Volltextzugriff (PDF)

Pharmacokinetics of thalidomide in an elderly prostate cancer population

Journal of pharmaceutical sciences, 1999-01, Vol.88 (1), p.121-125

1999

Volltextzugriff (PDF)

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

Cancer chemotherapy and pharmacology, 2006-03, Vol.57 (3), p.275-281

2006

Volltextzugriff (PDF)

Recent advances in pharmacogenetic approaches to anticancer drug development

Drug development research, 2004-07, Vol.62 (3), p.233-253

2004

Volltextzugriff (PDF)

A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer

Clinical cancer research, 1999-09, Vol.5 (9), p.2366-2373

1999

Volltextzugriff (PDF)

Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

Clinical cancer research, 2005-06, Vol.11 (11), p.4136-4143

2005

Volltextzugriff (PDF)

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer

International journal of cancer, 2016-10, Vol.139 (7), p.1648-1657

2016

Volltextzugriff (PDF)

Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro

International journal of nanomedicine, 2020-01, Vol.15, p.991-1003

2020

Volltextzugriff (PDF)

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

Leukemia, 2001-10, Vol.15 (10), p.1537-1543

2001

Volltextzugriff (PDF)

Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents

Journal of clinical oncology, 2004-06, Vol.22 (12), p.2489-2503

2004

Volltextzugriff (PDF)

Angiogenesis: An Integrative Approach from Science to Medicine

1. Aufl., 2008

Volltextzugriff (PDF)

Current status of thalidomide and its role in the treatment of metastatic prostate cancer

Critical reviews in oncology/hematology, 2003-06, Vol.46, p.49-57

2003

Volltextzugriff (PDF)

1 – 25 von 294

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(281)
Mit Volltextzugriff
(248)

Publikationsform

Sprache

Englisch
(294)

Erscheinungsjahr

n.n

Thema

Science & Technology
(271)
Life Sciences & Biomedicine
(264)
Humans
(250)
Male
(169)
Biological And Medical Sciences
(164)
Medical Sciences
(161)
Oncology
(130)
Pharmacology. Drug Treatments
(121)
Middle Aged
(110)
Aged
(97)
Antineoplastic Agents
(84)
Adult
(81)
Female
(81)
Chemotherapy
(77)
Pharmacology & Pharmacy
(75)
Prostatic Neoplasms - Drug Therapy
(64)
Animals
(50)
Prostatic Neoplasms - Pathology
(41)
Neoplasms - Drug Therapy
(38)
Antineoplastic Agents - Therapeutic Use
(37)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Thalidomide

Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

Thalidomide Metabolism by the CYP2C Subfamily

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform

A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-independent Prostate Cancer

Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

Review of UCN-01 Development: A Lesson in the Importance of Clinical Pharmacology

Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependent

Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues

Synthesis of Racemic cis-5-Hydroxy-3-phthalimidoglutarimide. A Metabolite of Thalidomide Isolated from Human Plasma

Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice

Thalidomide neuropathy in patients treated for metastatic prostate cancer

Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study

Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors

Pharmacokinetics of thalidomide in an elderly prostate cancer population

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

Recent advances in pharmacogenetic approaches to anticancer drug development

A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer

Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer

Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents

Angiogenesis: An Integrative Approach from Science to Medicine

Current status of thalidomide and its role in the treatment of metastatic prostate cancer

Suchergebnisse filtern